Abstract:Background: The immunometabolic mechanisms underlying variable responses to oral immunotherapy (OIT) in patients with IgE-mediated food allergy are unknown. Objective: To identify novel pathways associated with tolerance in food allergy, we used metabolomic profiling to find pathways important for food allergy in multi-ethnic cohorts and responses to OIT. Methods: Untargeted plasma metabolomics data were generated from the VDAART healthy infant cohort (N=384), a Costa Rican cohort of children with asthma (N=1040), and a peanut OIT trial (N=20) evaluating sustained unresponsiveness (SU, protection that lasts after therapy) versus transient desensitization (TD, protection that ends immediately afterwards). Generalized linear regression modeling and pathway enrichment analysis identified metabolites associated with food allergy and OIT outcomes. Results: Compared with unaffected children, those with food allergy were more likely to have metabolomic profiles with altered histidines and increased bile acids. Eicosanoids (e.g., arachidonic acid derivatives) (q=2.4×10 -20 ) and linoleic acid derivatives (q=3.8×10 -5 ) pathways decreased over time on OIT. Comparing SU versus TD revealed differing concentrations of bile acids (q=4.1×10 -8 ), eicosanoids (q=7.9×10 -7 ), and histidine pathways (q=0.015). In particular, the bile acid lithocholate (4.97[1.93,16.14], p=0.0027), the eicosanoid leukotriene B4 (3.21[1.38,8.38], p=0.01), and the histidine metabolite urocanic acid (22.13[3.98,194.67], p=0.0015) were higher in SU. Conclusions: We observed distinct profiles of bile acids, histidines, and eicosanoids that vary among patients with food allergy, over time on OIT and between SU and TD. Participants with SU had higher levels of metabolites such as lithocholate and urocanic acid, which have immunomodulatory roles in key T-cell subsets, suggesting potential mechanisms of tolerance in immunotherapy. Key messages: - Compared with unaffected controls, children with food allergy demonstrated higher levels of bile acids and distinct histidine/urocanic acid profiles, suggesting a potential role of these metabolites in food allergy. - In participants receiving oral immunotherapy for food allergy, those who were able to maintain tolerance-even after stopping therapyhad lower overall levels of bile acid and histidine metabolites, with the exception of lithocholic acid and urocanic acid, two metabolites that have roles in T cell differentiation that may increase the likelihood of remission in immunotherapy. Capsule summary: This is the first study of plasma metabolomic profiles of responses to OIT in individuals with IgE-mediated food allergy. Identification of immunomodulatory metabolites in allergic tolerance may help identify mechanisms of tolerance and guide future therapeutic development.

Differences in Familiarity with Oral Immunotherapy Among Caregivers of White and Black Food-Allergic Children

Racial and Ethnic Representation in Food Allergen Immunotherapy Trial Participants: A Systematic Review

Food Allergy Reaction Severity and Management in a Diverse Population

Food allergy epidemiology and racial and/or ethnic differences

Food allergy: Children's symptom levels are associated with mothers' psycho-socio-economic variables

Addressing common questions on food oral immunotherapy: a practical guide for paediatricians

Safety and feasibility of peanut, tree nut, and sesame oral immunotherapy in infants and toddlers in a real-world setting

Real-world experience: a retrospective pediatric chart review to determine why patients and caregivers discontinue oral immunotherapy

Alterations in Child Feeding Behavior: An Underrecognized Clinical Complication of Food Allergy

Food aversion and anxiety represent primary patient barriers to food oral immunotherapy

Alterations in Child Feeding Behavior: An Under-Recognized Clinical Complication of Food Allergy

Sociodemographic inequities in food allergy: Insights on food allergy from birth cohorts

Racial, Ethnic, and Language Inequities in Ambulatory Pediatrics Patient Family Experience

Implementing Food Oral Immunotherapy Into Clinical Practice: Quality and Safety Perspectives From a US Academic Center

Including young children in their food allergy care: A pilot study

Development and acceptability of a decision-aid for food allergy Oral immunotherapy in children

Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent

Transcriptomic changes associated with oral immunotherapy for food allergy

Metabolomics of IgE-Mediated Food Allergy and Oral Immunotherapy Outcomes based on Metabolomic Profiling

Psychosocial Mediators of Change and Patient Selection Factors in Oral Immunotherapy Trials

Weighing the benefits and risks of oral immunotherapy in clinical practice